%0 Journal Article
%T Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
%A Andrew B Lassman
%A Andrew M Scott
%A David A Reardon
%A David Maag
%A Earle Bain
%A Erica Gomez
%A Hao Xiong
%A Helen Wheeler
%A Ho-Jin Lee
%A Hui K Gan
%A John Simes
%A Kyle D Holen
%A Kyriakos P Papadopoulos
%A Lisa Roberts-Rapp
%A Louis B Nabors
%A Marta Penas-Prado
%A Martin J van den Bent
%A Nicholas Butowski
%A Peter J Ansell
%A Priya Kumthekar
%A Ryan Merrell
%A Tobias Walbert
%A Tom Mikkelsen
%A Zarnie Lwin
%J Archive of "Neuro-Oncology".
%D 2019
%R 10.1093/neuonc/noy091
%X Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody¨Cdrug conjugate depatuxizumab mafodotin (depatux-m) binds cells with EGFR amplification, is internalized, and releases a microtubule toxin, killing the cell. Here we report efficacy, safety and pharmacokinetics (PK) of depatux-m + temozolomide (TMZ) in patients with EGFR-amplified rGBM
%K ABT-414
%K antibody¨Cdrug conjugate
%K depatux-m
%K EGFR amplification
%K rGBM
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303422/